tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate | 133333-27-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate
• 英文别名: (5S,1'S)-5-(1'-((1,1-dimethylethoxy-carbonyl)amino)-2'-phenylethyl)-4,5-dihydrofuran-2-(3H)-one；(5S)-5-[(1S)-1-(t-Boc-amino)-2-phenylethyl]-dihydro-furan-2(3H)-one；(5S,1'S)-5-(1-(Boc-amino)-2-phenylethyl)dihydrofuran-2(3H)-one；5(S)-[1(S)-(Boc-amino)-2-phenylethyl]-dihydrofuran-2-(3H)-one；5(S)-[1(S)-(Boc-amino)-2-phenylethyl]dihydrofuran-2-(3H)-one；tert-butyl(1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate；tert-butyl N-[(1S)-1-[(2S)-5-oxooxolan-2-yl]-2-phenylethyl]carbamate
• CAS: 133333-27-4
• 化学式: C₁₇H₂₃NO₄
• 分子量: 305.374
• InChiKey: YZDUNYUENNWBRE-KBPBESRZSA-N

物化性质

• 沸点：
  490.5±28.0 °C(Predicted)
• 密度：
  1.141±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate 在 N-甲基吗啉 、 咪唑 、 盐酸 、 sodium hydroxide 、 3> 、 乙二胺四乙酸 、 1-羟基苯并三唑 、 lithium hexamethyldisilazane 、 儿萘酚硼烷 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 66.83h， 生成 (S)-N-((1S,2S,4R)-1-Benzyl-2,7-dihydroxy-4-isobutylcarbamoyl-heptyl)-2-tert-butoxycarbonylamino-succinamic acid benzyl ester
  参考文献：
  名称：

  Rational design and synthesis of selective BACE-1 inhibitors

  摘要：

  An effective approach for enhancing the selectivity of beta-site amyloid precursor protein cleaving enzyme (BACE 1) inhibitors is developed based on the unique features of the S1' pocket of the enzyme. A series of low molecular weight ( < 600) compounds were synthesized with different moieties at the P1' position. The selectivity of BACE 1 inhibitors versus cathepsin D and renin was enhanced 120-fold by replacing the hydrophobic propyl group with a hydrophilic propionic acid group. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.061
• 作为产物：
  描述：

  (1'R,2'S)-2-<2'--1'-<(tert-butyldimethylsilyl)oxy>-3'-phenylpropyl>-1,3-thiazole 在 sodium tetrahydroborate 、 4 A molecular sieve 、 四丁基氟化铵 、 copper(II) oxide 、 copper dichloride 、 nickel dichloride 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 、 乙腈 为溶剂， 反应 48.92h， 生成 tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate
  参考文献：
  名称：

  Thiazole-Based Stereoselective Routes to Leucine and Phenylalanine Hydroxyethylene Dipeptide Isostere Inhibitors of Renin and HIV-1 Aspartic Protease

  摘要：

  A new synthesis of hydroxyethylene dipeptide isosteres for Leu-Leu and Phe-Phe in their gamma-lactone form 1a and 1b employing beta-amino-alpha-hydroxy aldehydes with singly and doubly protected nitrogen has been developed. These key intermediates, which are available through the thiazole-aldehyde synthesis from L-leucine and L-phenylalanine, were converted to alkanoates by Wittig olefination and reduction of the ethylenic double bond. Lactonization and stereoselective alkylation at C-2 of the resulting lactones completed the building up of the structural framework. Overall yields were in the range 16-19% for 1a and 22-23% for 1b.

  DOI：

  10.1021/jo00129a037
• 作为试剂：
  描述：

  tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate 、 2,3,4-trimethoxybenzyl iodide 在 tert-butyl (1S)-1-[(2S)-5-oxotetrahydrofuran-2-yl]-2-phenylethylcarbamate 作用下， 以85的产率得到5(S)-[1(S)-(Boc-amino)-2-phenylethyl]-3(R)-(2,3,4-trimethoxyphenylmethyl)-dihydrofuran-2-(3H)-one
  参考文献：
  名称：

  Arch. Pharm. Pharm. Med. Chem. 1996, 329, 273-278

  摘要：

  DOI：

文献信息

• 5-amino-4-hydroxyhexanoic acid derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05643878A1

  公开（公告）日：1997-07-01

  Compounds of formula I ##STR1## or their hydroxy-protected derivatives, and compounds of formula I' ##STR2## wherein T is an acyl radical of formula Z ##STR3## wherein R.sup.z is unsubstituted or substituted hydrocarbyl wherein at least one carbon atom has been replaced by a hetero atom with the proviso that a hetero atom is not bonded directly to the carbonyl to which the radical R.sup.z is bonded, alkyl having two or more carbon atoms, lower alkenyl, lower alkynyl, aryl or unsubstituted or substituted amino, and wherein the radicals R.sub.1, B.sub.1, R.sub.2, R.sub.3, A.sub.1, A.sub.2 and NR.sub.4 R.sub.5 are as defined in the description, and precursors thereof, are described. The compounds have pharmaceutical activity, for example in the treatment of retroviral diseases, such as AIDS.

  公式I的化合物##STR1##或其羟基保护衍生物，以及公式I'的化合物##STR2##，其中T是公式Z的酰基自由基##STR3##，其中R.sup.z是不取代或取代的碳氢化合物，至少有一个碳原子被杂原子替换，但需满足杂原子不直接与R.sup.z连接的酰基相连，烷基含有两个或更多碳原子，低级烯基，低级炔基，芳基或不取代或取代的氨基，且其中R.sub.1、B.sub.1、R.sub.2、R.sub.3、A.sub.1、A.sub.2和NR.sub.4 R.sub.5如描述中定义，以及它们的先驱物，都有药物活性，例如在治疗反转录病毒疾病，如艾滋病。
• HIV protease inhibitors useful for the treatment of aids
  申请人：MERCK & CO. INC.

  公开号：EP0534511A1

  公开（公告）日：1993-03-31

  Compounds of the form,         A-G-J    wherein A is an amine protecting group or urethane, G a dipeptide isostere and J a small terminal group are described. They are distinguished by tetrahydrofuryl or tetrahydropyranyl substituents, and the like. These compounds are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

  形式为A-G-J的化合物被描述，其中A是胺保护基或脲醚，G是二肽同分异构体，J是小的末端基团。它们以四氢呋喃基或四氢吡喃基取代等方式进行区分。这些化合物在抑制HIV蛋白酶、预防或治疗HIV感染以及治疗艾滋病方面具有用途，无论是作为化合物、药学上可接受的盐、药用组合成分，还是与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。还描述了治疗艾滋病的方法以及预防或治疗HIV感染的方法。
• Structure-Based Design:  Potent Inhibitors of Human Brain Memapsin 2 (β-Secretase)
  作者：Arun K. Ghosh、Geoffrey Bilcer、Cynthia Harwood、Reiko Kawahama、Dongwoo Shin、Khaja Azhar Hussain、Lin Hong、Jeffrey A. Loy、Chan Nguyen、Gerald Koelsch、Jacques Ermolieff、Jordan Tang

  DOI：10.1021/jm0101803

  日期：2001.8.1

  Memapsin 2 (beta-secretase) is one of two proteases that cleave the beta-amyloid precursor protein (APP) to produce the 40-42 residue amyloid-beta peptide (Abeta) in the human brain, a key event in the progression of Alzheimer's disease. On the basis of the X-ray crystal structure of our lead inhibitor (2, OM99-2 with eight residues) bound to memapsin, we have reduced the molecular weight and designed

  Memapsin 2（beta-secretase）是两种蛋白酶，它们会切割β-淀粉样蛋白前体蛋白（APP）在人脑中产生40-42个残基的淀粉样β-肽（Abeta），这是阿尔茨海默氏病进展的关键事件疾病。基于我们的铅抑制剂（2个，带有八个残基的OM99-2，具有8个残基）的X射线晶体结构，我们降低了分子量，并设计了有效的Memapsin抑制剂。已经提出了基于结构的设计和初步的结构活性研究。
• Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application
  作者：Bart Kesteleyn、Katie Amssoms、Wim Schepens、Geerwin Hache、Wim Verschueren、Wim Van De Vreken、Klara Rombauts、Greet Meurs、Patrick Sterkens、Bart Stoops、Lieven Baert、Nigel Austin、Jörg Wegner、Chantal Masungi、Inge Dierynck、Stina Lundgren、Daniel Jönsson、Kevin Parkes、Genadiy Kalayanov、Hans Wallberg、Åsa Rosenquist、Bertil Samuelsson、Kristof Van Emelen、Jan Willem Thuring

  DOI：10.1016/j.bmcl.2012.10.095

  日期：2013.1

  The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1–22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe–Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing

  描述了新型HIV-1蛋白酶抑制剂（PIs）（1-22）的设计和合成，这些抑制剂对HIV-1野生型和耐多种PI的HIV突变体临床分离株显示出高效力。铅优化从化合物1（一种Phe-Phe羟乙烯拟肽PI）开始，并旨在发现适用于长效（LA）注射药物应用的新PI。引入杂环6-甲氧基-3-吡啶基或6-（二甲基氨基）-3-吡啶基部分（R 3在）对位P1'苄基片段的位置在低个位数纳摩尔范围内具有抗病毒效力的化合物。各种芳香环上新陈代谢热点的卤化或烷基化导致PI对人肝微粒体的降解具有很高的稳定性，并且在大鼠中的血浆清除率较低。更换chromanolamine部分（R 1在P2）蛋白酶由cyclopentanolamine或cyclohexanolamine衍生物的结合位点提供了一系列的高清除率的PI（16 - 22与EC）50的HIV-1中的0.8-范围上野生型S 1.8 nM。效绩指标18和22制成纳米混
• Antiviral ethers of aspartate protease substrate isosteres
  申请人：Ciba-Geigy Corporation

  公开号：US05663200A1

  公开（公告）日：1997-09-02

  Antiretroviral compounds (which are effective, for example, against HIV) of the formula I ##STR1## in which R.sub.1 is an acyl radical lower-alkoxyl-lower-alkanoyl whose lower alkoxy radical is unsubstituted or is substituted by halogen, phenyl, lower alkoxy or a heterocyclic radical selected from piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolidinyl, thiazolyl, indolyl or 4H-1-benzopyranyl which is unsubstituted or substituted by oxo, hydroxyl, amine, lower alkyl, lower-alkoxycarbonyl and/or phenyl-lower-alkoxycarbonyl; lower alkanoyl which is unsubstituted or is substituted by one of the said unsubstituted or substituted heterocyclic radicals; arylcarbonyl or heterocyclylcarbonyl which are substituted by heterocyclyl or heterocyclyl-lower-alkyl; phenyl-lower-alkanoyl which is substituted by hydroxyl and lower alkyl; or arylsulfonyl; or the residue of an amino acid which is defined in accordance with the description (and which may be acylated on the amino nitrogen by one of the abovementioned acyl radicals); R.sub.2 and R.sub.3 are in each case cyclohexyl, cyclohexenyl, phenyl, naphthyl or tetrahydronaphthyl which are unsubstituted or substituted by lower alkyl, phenyl, cyanophenyl, phenyl-lower-alkyl, halogen, halo-lower-alkyl, cyano, hydroxyl, lower alkoxy, phenyl-lower-alkoxyl, pyridyl-lower-alkoxy, lower-alkoxy-lower-alkoxy, lower-alkoxycarbonyl-lower-alkoxy, carboxyl-lower-alkoxy, hydroxyl-lower-alkoxy, carbamoyl-lower-alkoxy, cyano-lower-alkoxy, and phenyl-lower-alkanesulfonyl which is unsubstituted or substituted by halogen; R.sub.4 is lower alkyl, cyclohexyl or phenyl; and R.sub.5 is lower alkyl; and n is 1 or 2, or salts thereof, are novel.

  抗逆转录病毒化合物（例如对抗HIV有效）的化学式为I ##STR1## 其中R.sub.1是酰基基团的低烷氧基-低烷酰基，其低烷氧基团未取代或被卤素、苯基、低烷氧基或从哌啶基、吡咯啉基、四氢吡喃基、四氢呋喃基、噻唑啉基、噻唑基、吲哚基或4H-1-苯并吡喃基中选择的杂环基团取代；未取代或被上述未取代或取代的杂环基团之一取代的低烷酰基；被杂环基或杂环基-低烷基取代的芳基酰基或杂环基酰基；被羟基和低烷基取代的苯基-低烷酰基；或芳基磺酰基；或根据描述定义的氨基酸残基（可能在氨基氮上由上述酰基基团之一酰化）；R.sub.2和R.sub.3分别为环己基、环己烯基、苯基、萘基或四氢萘基，未取代或被低烷基、苯基、氰苯基、苯基-低烷基、卤素、卤代低烷基、氰基、羟基、低烷氧基、苯基-低烷氧基、吡啶基-低烷氧基、低烷氧基-低烷氧基、低烷氧基羰基-低烷氧基、羧基-低烷氧基、羟基-低烷氧基、氨基甲酰基-低烷氧基、氰基-低烷氧基和未取代或被卤素取代的苯基-低烷烷基磺酰基取代；R.sub.4为低烷基、环己基或苯基；R.sub.5为低烷基；n为1或2，或其盐，均为新颖的。